A phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer

Citation
Al. Thomas et al., A phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer, CANC CHEMOT, 48(4), 2001, pp. 266-268
Citations number
13
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
ISSN journal
0344-5704 → ACNP
Volume
48
Issue
4
Year of publication
2001
Pages
266 - 268
Database
ISI
SICI code
0344-5704(200110)48:4<266:APISOC>2.0.ZU;2-7
Abstract
Purpose: A phase II study was designed to assess the efficacy and safety of Caelyx (liposomal doxorubicin) in patients with advanced or metastatic gas tric cancer. Methods: A total of 25 patients with gastric adenocarcinoma we re treated with Caelyx 45 mg/m(2) every 28 days as first-line therapy for a dvanced disease. Patients were treated until tumour progression or unaccept able toxicity. Results: One patient was withdrawn from the study after expe riencing a severe infusion reaction. Of the 24 evaluable patients, I had a partial response. 7 had stable disease and the others progressed. Side effe cts, in articular palmar-plantar erythrodysaesthesia and haematological tox icity, were minor. Conclusions: We conclude that while tl is dose and sched ule of Caelyx in this patient group is acceptable. further studies with thi s regimen cannot be recommended due to the lack of antitumour activity seen .